A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT05139615 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Acute Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: APD418
DRUG: APD418
DRUG: Placebo

Sponsor

Pfizer

Collaborators

[object Object]